In Brief: Paradigm Medical
This article was originally published in The Gray Sheet
Executive Summary
Paradigm Medical: "Software and hardware problems" with the company's Precisionist Thirty Thousand phacoemulsification system "have been corrected and shipments resumed Sept. 18," the company says. The system, cleared by FDA via 510(k) in October 1995, "is based on a workstation manufacturing approach that allows [Precisionist's] ultrasound system to be upgraded to its Photon laser system" once it is cleared by FDA. Paradigm submitted a 510(k) for the Photon system in 1994 ("The Gray Sheet" April 22, 1996, I&W-12). Paradigm also announces 510(k) clearance for the Ocular Flow Analyzer, which measures intraocular pressure and calculates pulsatile blood flow through the eye...
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.